NBI-31772 hydrate

• CAT Number: I045636
• Molecular Formula: C17H11NO7.7/4H2O
• Molecular Weight: 372.82
• Purity: ≥95%

NBI-31772 hydrate (Cat No.: I045636) is a small-molecule inhibitor that disrupts the interaction between insulin-like growth factor binding proteins (IGFBPs) and insulin-like growth factors (IGFs). By releasing IGFs from IGFBPs, it enhances IGF signaling, which plays critical roles in cell growth, survival, and metabolism. Researchers use NBI-31772 hydrate to study IGF pathway regulation, cancer biology, and metabolic disorders. The hydrate form provides stability for experimental use. Although not intended for therapeutic application, it remains a valuable pharmacological tool in growth factor–related biomedical research.

Reference

[1]. Liu XJ, et al. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem. 2001 Aug 31;276(35):32419-22.
[Content Brief]

[2]. De Ceuninck F, et al. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther. 2004;6(5):R393-403.
[Content Brief]

[3]. Malberg JE, et al, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Nov;32(11):2360-8.
[Content Brief]